https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-30 / Cell Adh Migr 2010 Jan-Mar;4(1):153-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-30 / Cell Adh Migr 2010 Jan-Mar;4(1):153-612010-01-30 00:00:002019-02-15 08:50:36What’s the place of immunotherapy in malignant mesothelioma treatments?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-29 / Curr. Opin. Immunol. 2010 Feb;22(1):137-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-29 / Curr. Opin. Immunol. 2010 Feb;22(1):137-442010-01-29 00:00:002019-02-15 08:44:07Presentation of tumour antigens by dendritic cells and challenges faced
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-25 / Oncogene 2010 Apr;29(15):2205-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-25 / Oncogene 2010 Apr;29(15):2205-162010-01-25 00:00:002019-02-15 09:21:49Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-06 / BMC Cancer 2010 Jan;10:5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-06 / BMC Cancer 2010 Jan;10:52010-01-06 00:00:002019-02-15 08:43:59Tocotrienols are good adjuvants for developing cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / J. Virol. 2010 Jan;84(1):639-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / J. Virol. 2010 Jan;84(1):639-462010-01-01 00:00:002010-01-01 00:00:00The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Int J Hyperthermia 2010;26(2):118-26
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Int J Hyperthermia 2010;26(2):118-262010-01-01 00:00:002010-01-01 00:00:00Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Int J Hyperthermia 2010;26(7):612-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Int J Hyperthermia 2010;26(7):612-72010-01-01 00:00:002010-01-01 00:00:00Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):111-23
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):111-232010-01-01 00:00:002019-02-15 08:48:31Heat shock proteins in glioblastomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Neoplasma 2010;57(5):455-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Neoplasma 2010;57(5):455-642010-01-01 00:00:002019-02-15 08:50:55Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Curr. Med. Chem. 2010;17(27):3045-57
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Curr. Med. Chem. 2010;17(27):3045-572010-01-01 00:00:002019-02-15 09:17:27Biological rationales and clinical applications of temperature controlled hyperthermia–implications for multimodal cancer treatments
